Business Description
Athersys Inc
NAICS : 325412
SIC : 2834
Description
Athersys Inc is a biotechnology company. It is focused on developing novel and proprietary therapies in the areas where there is an unmet medical need, particularly in the regenerative medicine area. The firm's main product is Multistem cell therapy. Its current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders and certain pulmonary conditions. Its revenue has been derived from corporate collaborations, license agreements, and government grants.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.44 | |||||
| Equity-to-Asset | -0.33 | |||||
| Debt-to-Equity | -0.79 | |||||
| Debt-to-EBITDA | -0.11 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -26.62 | |||||
| Beneish M-Score | 6.47 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -47.6 | |||||
| 3-Year EBITDA Growth Rate | -28 | |||||
| 3-Year EPS without NRI Growth Rate | -29.4 | |||||
| 3-Year FCF Growth Rate | -47 | |||||
| 3-Year Book Growth Rate | -39.3 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 49.34 | |||||
| 9-Day RSI | 37.84 | |||||
| 14-Day RSI | 34.32 | |||||
| 6-1 Month Momentum % | -80.35 | |||||
| 12-1 Month Momentum % | -90.88 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.64 | |||||
| Quick Ratio | 0.64 | |||||
| Cash Ratio | 0.4 | |||||
| Days Sales Outstanding | 68.91 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -18.9 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -786.94 | |||||
| Net Margin % | -779.67 | |||||
| ROE % | -640.98 | |||||
| ROA % | -146.55 | |||||
| ROIC % | -429.48 | |||||
| ROC (Joel Greenblatt) % | -680.18 | |||||
| ROCE % | -311.46 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 34.24 | |||||
| EV-to-EBIT | -5.49 | |||||
| EV-to-EBITDA | -5.59 | |||||
| EV-to-Revenue | 43.27 | |||||
| EV-to-Forward-Revenue | 0.11 | |||||
| EV-to-FCF | -6.32 | |||||
| Price-to-Median-PS-Value | 0.04 | |||||
| Earnings Yield (Greenblatt) % | -18.2 |
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ATHX
Executives
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 10.742 | ||
| EPS (TTM) ($) | -0.34 | ||
| Beta | -1.82 | ||
| Volatility % | 77.31 | ||
| 14-Day RSI | 34.32 | ||
| 14-Day ATR ($) | 0.438354 | ||
| 20-Day SMA ($) | 2.0295 | ||
| 12-1 Month Momentum % | -90.88 | ||
| 52-Week Range ($) | 1.13 - 35.5 | ||
| Shares Outstanding (Mil) | 305.11 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Athersys Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Athersys Inc Analysis
Share your researchHeadlines
See More
No news.